http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2648228-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2013-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af30bca60dcaf32243ea370e5bca7cc6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b9910162ce50061936f8cff5f7df01f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22493beef9495a2e338ab14b354f9215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0a5e2ea07e45f05fa3e64e4fce6d7d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06b1aa25931371968fba0a2ad2047ef3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12d9efd07616089926fa40a3f56c1eff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_682385e8c59f12eab2528decc2c01278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e68671f7277ae4c0f9810c1418f40c5 |
| publicationDate | 2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2648228-T3 |
| titleOfInvention | Imidazo [1,2-b] pyridazine derivatives as kinase inhibitors |
| abstract | A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof: ** Formula ** in which R1 represents a hydrogen atom, a C1-C6 alkyl group, a fluoro-C1-C6 alkyl group or a C1-C6 hydroxyalkyl group; Q represents an oxygen atom or RaN, where Ra represents a hydrogen atom or a C1-C6 alkyl group; G represents a phenyl group or a 5- or 6-membered heteroaryl group having, in the ring, from 1 to 3 heteroatoms independently selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, in wherein the 5-membered heteroaryl group optionally has 1 or 2 substituents independently selected from the group consisting of a halogen atom, a cyano group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a dihalo-alkyl group C1-C6 and a trihalo-C1-C6 alkyl group, and the phenyl group and the 6-membered heteroaryl group each optionally have 1 to 3 substituents independently selected from the group consisting of a 5- or 6-membered heteroaryl group which it has, in the ring, from 1 to 3 heteroatoms independently selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, a halogen atom, a cyano group, an alky group lo C1-C6, a C1-C6 alkoxy group and a trihalo-C1-C6 alkyl group; T represents a nitrogen atom or CRb, where Rb represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group or a cyano group; Y1 and Y2 each independently represent a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group or a cyano group; and each of Y3 and Y4 independently represents a hydrogen atom, a group selected from group A described below, or a group represented by the following formula (II): ** Formula ** in which W represents an atom oxygen or CRcRd, where each of Rc and Rd independently represents a hydrogen atom, a C1-C6 alkyl group or an amino group, or Rc and Rd optionally form a C3-C6 cycloalkyl group together with the carbon atom linked to Rc and Rd; n represents 0, 1 or 2; R2 and R3 each independently represent a hydrogen atom, an amino group, a C1-C6 alkyl group, an amino-C1-C6 alkyl group, a C1-C6 alkylamino group or a di-C1-C6 alkylamino group, with the condition that one of Y3 and Y4 inevitably represents a hydrogen atom and the other group represents a group other than a hydrogen atom, group A: -OM, -SM and -NH-M, where M represents a C1-C6 alkyl group having 1 or 2 substituents independently selected from group B described below, a C3-C6 amino-cycloalkyl group, a 4- to 6-membered aliphatic heterocyclic group having a ring nitrogen atom , or a 5- or 6-membered aliphatic heterocyclic group having 1 or 2 substituents independently selected from group D described below and having a ring nitrogen atom, group B: an amino group, a hydroxy group , a C1-C6 alkylamino group, a di-alk group C1-C6 ylamino, a C3-C6 cycloalkylamino group, a C3-C6 amino-cycloalkyl group, a C1-C6 hydroxy-alkylamino group, a 4- to 6-membered aliphatic heterocyclic group having a ring nitrogen atom, and a 6-membered aliphatic heterocyclic group having one nitrogen atom and one ring oxygen atom, the 4-6 membered aliphatic heterocyclic group having one ring nitrogen atom and the 6-membered aliphatic heterocyclic group having a nitrogen atom and an oxygen atom in the ring each optionally having 1 or 2 substituents independently selected from group C described below, group C: a halogen atom, a C1-C6 alkyl group and a hydroxy-C1-C6 alkyl group, and group D: an amino group and a halogen atom. |
| priorityDate | 2012-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 739.